z-logo
open-access-imgOpen Access
Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy Type 1: A Light on Molecular Mechanisms
Author(s) -
Koen L. A. Vanderschuren,
Tom Sieverink,
Ronald Wilders
Publication year - 2013
Publication title -
genetics research international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.351
H-Index - 9
eISSN - 2090-3154
pISSN - 2090-3162
DOI - 10.1155/2013/460805
Subject(s) - arrhythmogenic right ventricular dysplasia , cardiomyopathy , medicine , ventricle , dysplasia , smad , transforming growth factor , cardiology , heart failure
Arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C) is an inherited cardiomyopathy associated with cardiac arrhythmias originating in the right ventricle, heart failure, and sudden cardiac death. Development of ARVD/C type 1 has been attributed to differential expression of transforming growth factor beta 3 (TGF β 3). Several mechanisms underlying the molecular basis of ARVD/C type 1 have been proposed. Evaluating previously described mechanisms might elucidate how TGF β 3 contributes to disease progression in ARVD/C type 1. Here we review how TGF β 3 can induce fibrogenesis through Smad and/or β -catenin signaling. Moreover, the role of apoptosis is addressed. Finally the extent to which the immune system has been demonstrated to be a modulating and amplifying agent in the onset and progression of ARVD/C in general is discussed.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom